Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192865 | 0.80 | CYP3A4 (0.42) | LMNADPP4CYP3A4CYP2C9PKM | |
| SCHEMBL5361035 | 0.79 | TSHR (0.33) | DPP4TSHR | |
| SCHEMBL24421368 | 0.77 | LMNA (0.33) | LMNADPP4 | |
| SCHEMBL1972216 | 0.76 | TSHR (0.40) | LMNACYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL1973582 | 0.76 | USP2 (0.39) | LMNACYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL5357532 | 0.76 | TSHR (0.36) | CYP3A4CYP2C9PKMCYP2C19TSHR | |
| SCHEMBL12436912 | 0.74 | LMNA (0.36) | LMNADPP4 | |
| SCHEMBL5348545 | 0.73 | ALDH1A1 (0.36) | LMNADPP4CYP2C19TSHR | |
| SCHEMBL5360437 | 0.72 | LMNA (0.34) | LMNADPP4CYP3A4CYP2C9PKM | |
| SCHEMBL5348681 | 0.71 | ALDH1A1 (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300953-B2 | Process for preparing nitrile compound, carboxylic acid compound or carboxylic acid ester compound | UBE INDUSTRIES, LTD (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060287541-A1 | Subjecting a 4-substituted tetrahydropyran-4-carboxylic acid compound to to decarboxylation in the presence of a metal catalyst for producing 4-substituted tetrahydropyran | UBE INDUSTRIES, LTD. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1671937-A1 | METHOD FOR PRODUCING NITRILE COMPOUND, CARBOXYLIC ACID COMPOUND OR CARBOXYLATE COMPOUND | Ube Industries, Ltd. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287541-A1 | Subjecting a 4-substituted tetrahydropyran-4-carboxylic acid compound to to decarboxylation in the presence of a metal catalyst for producing 4-substituted tetrahydropyran | CBR1, ALDH18A1, ME1 | LMNA 4534/4885DPP4 1881/4885CYP3A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.